
Abstract Objective To construct and validate a contrast-enhanced ultrasound (CEUS) radiomics-clinical model for predicting transarterial chemoembolization (TACE) resistance in hepatocellular carcinoma (HCC). Methods A total of 168 HCC patients who underwent CEUS on two vendor platforms (Philips E9 and GE Logiq E95) were split into a training set (n = 118) and an internal validation set (n = 50), with an additional 80 patients forming an external validation cohort. For each patient, 2D regions of interest were manually delineated on the largest cross-sectional slice of each CEUS phase. Radiomic features were extracted and screened by LASSO regression; the twelve retained features were linearly combined into a single Rad-score. The Rad-score and three prespecified clinical risk factors (tumor size, Child-Pugh class, AFP) confirmed by multivariate analysis were combined into a parsimonious logistic regression (LR) model with four predictors in total. Performance was assessed by ROC curve, calibration curve, decision curve analysis (DCA), subgroup analysis, and prospective validation. Results The combined model had AUCs of 0.895, 0.891 and 0.846 in three sets, with subgroup AUCs >0.86. Prospective validation showed TACE plus sorafenib improved 6-month response rate from 26.7% to 53.3% for high-risk patients. Conclusion The CEUS radiomics-clinical model accurately predicts TACE resistance, guiding individualized HCC treatment. Advances in Knowledge This model integrates CEUS multi-phase radiomics and clinical factors, outperforming single clinical/radiomic models. Strict multi-step screening and comprehensive validation avoid data leakage, ensuring robust prediction and clinical translatability.
Abstract: In transarterial radioembolization (TARE) for liver metastases, dosimetry is essential to optimize therapeutic response while minimizing toxicity. Dose planning or pre-treatment dosimetry have evolved from empirical and single-compartment models to multi-compartment approaches, leading to improved tumour response and overall survival. More recently, voxel-based dosimetry has emerged as an advanced technique that provides high-resolution spatial dose mapping. Dose verification or post-treatment dosimetry using post-treatment imaging is essential for establishing dose-response relationships and defining clinically relevant dose thresholds. Even when such thresholds are proposed, their translation into clinical practice is challenging due to the numerous uncertainties introduced throughout the radioembolization workflow. Several physical and biological factors, including the effects of microsphere density remain insufficiently understood, making it difficult to determine their true impact on treatment outcomes. Collectively, these challenges underscore the need for standardized dosimetric methodologies and more robust evidence to enable reliable, personalized dose planning and verification, ultimately improving outcomes and expand the indications of radioembolization for liver metastasis.
Abstract Objectives In this study, we compared full protocol MR enterography (including contrast-enhanced images) and modified non-contrast protocol in assessment of CD activity. Material and method In this retrospective cross-sectional study, we included 182 patients with histologically confirmed CD who underwent MR enterography examination in ANONYMISED. For all patients, CD activity was interpreted by two independents, first based on abbreviated protocol (including T2-weighted imaging and balanced steady-state free precession (b-SSFP)) and then based on full protocol MRI. Agreement was assessed by concordance rates and Cohen's kappa. Results We found a high inter-modality agreement in CD activity assessment, with abbreviated non-contrast MRE demonstrating 98.4% concordance (179/182 cases) to contrast-enhanced MRE. Discordant findings (1.6%, 3/182) included one case misclassified as fibrostenotic and two as non-specific findings. Inter-reader agreement in MR enterography examination was also high (κ = 0.977 for final diagnosis, κ = 0.969 for fibrostenosis, and κ = 0.978 for comb sign detection), supporting high reproducibility between two radiologists. Conclusion Our findings demonstrate that abbreviated MR enterography (including T2-weighted sequence and b-SSFP) had substantial agreement with full protocol MR enterography in CD activity assessment, supporting its value as a reliable contrast-free alternative for practicing in clinical centers. Advances in knowledge Our investigation represents an advancement in CD imaging, leveraged by a large sample size, rigorous methodology, and comprehensive evaluation of different CD characterizations.
Abstract Objectives To evaluate the prevalence and clinical significance of incidental findings (IF) detected by Total-body 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in a genuinely asymptomatic cohort of blood donors. Methods 117 healthy, asymptomatic blood donors underwent ultra-low-dose FDG-PET/low-dose CT. The primary objective was to create an atlas of glucose metabolism in healthy individuals. A secondary objective was to assess the frequency and nature of IF, informing future considerations of the clinical value of potential screening programs. Here we report on IF. Results IF were detected in 64 participants (55%), with 51 (44%) presenting clinically insignificant IF and 13 (11%) clinically significant IF. Common insignificant IF included benign or inflammatory metabolic activity in the esophagus or lung parenchyma (n = 19), metabolically active reactive lymph nodes (n = 14), and degenerative skeletal changes (n = 13). Clinically significant IF comprised pathologically metabolically active cysts and polyps (n = 8), significantly enlarged vessels (n = 1), suspected malignant tumors (n = 1), large lipomas (n = 1), sarcoidosis (n = 1), and liver steatosis (n = 1). Conclusions This is the first study to systematically investigate incidental findings in an asymptomatic cohort using ultra-low-dose total-body FDG-PET/CT. Even in this highly selected population, numerous IFs were revealed, underscoring the need for risk-stratified, data-driven screening strategies integrating genetic biomarkers identifying individuals who will truly benefit. Advances in knowledge This first study of ultra-low-dose total-body FDG-PET/CT in asymptomatic donors found frequent incidental findings (55%, 11% clinically significant), establishing lower-bound estimates and supporting risk-stratified screening approaches.